Forum Topic News
  • Conversation: FDA approves first treatment for Lambert-Eaton myasthenic syndrome (LEMS) in adults

    • December 3, 2018 10:47 AM GMT
    • FDA approves first treatment for Lambert-Eaton myasthenic syndrome (LEMS) in adults

      The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.
      "There has been a long-standing need for a treatment for this rare disorder," said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "Patients with LEMS have significant weakness and fatigue that can often cause great difficulties with daily activities."
      In people with LEMS, the body's own immune system attacks the neuromuscular junction (the connection between nerves and muscles) and disrupts the ability of nerve cells to send signals to muscle cells. LEMS may be associated with other autoimmune diseases, but more commonly occurs in patients with cancer such as small cell lung cancer, where its onset precedes or coincides with the diagnosis of cancer. The prevalence of LEMS is estimated to be three per million individuals worldwide.
      Read more: https://prn.to/2Sox985

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč